. 2022 May 18;116(11):1032–1042. doi: 10.1093/trstmh/trac036

Table 2.

VNT antibody titre in acute and follow-up serum samples for patients with positive anti-JEV IgM capture ELISA

			Before IgG depletion (standard VNT)									After IgG depletion (IgM-VNT)
					NAb titre									NAb titre
Patient number	Sample type	Days of illness	Class	JEV IgG	JEV	D1	D2	D3	D4	ZIK	WN	Class	JEV IgG	JEV	D1	D2	D3	D4	ZIK	WN
1597	Adm	5	Conf	−	1280	Neg	Neg	Neg	Neg			Conf	−^a	160^b	Neg^b	Neg^b	Neg^b	Neg^b		Neg^b
	FU	59		+	2560	14	14	Neg	20					640^b	Neg^b	Neg^b	Neg^b	Neg^b
1704	Adm	5	Conf	+	640	20	Neg	20	28			Conf	−	640^b	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b
	FU	13		+	2560	40	Neg	28	80					2560 ^b	20^b	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b
829	Adm	4	Conf	−	1280	Neg	Neg	Neg	Neg	Neg	14	Conf	−	640^b	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b
	FU	21		+	2560	Neg	Neg	Neg	14	Neg^b
908	Adm	4	Conf	+	40	160	160	40	113	Neg		Conf
	FU	14		+	2560	20	Neg	Neg	14				−	2560	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b
928	Adm	5	Conf	−	1810	20	Neg	Neg	Neg	Neg	56	Conf	−	2560 ^b	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b
	FU	44		+	2560	Neg	Neg	Neg	14				−	2560	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b
2078	Adm	7	Conf	Eq	160	20	Neg	Neg	Neg			Conf	−
	FU	17		+	2560	Neg	Neg	20	20				−	≥2560	Neg	Neg	Neg	Neg
101	Adm	4	Conf	−	2560	Neg	Neg	Neg	Neg			Conf	−	453	Neg	Neg	Neg	Neg
	FU	6		−	2560	Neg	Neg	40	Neg				−	≥2560	Neg	Neg	Neg	Neg

1610	Adm	6	Comp	+	2560	14	Neg	Neg	20			Conf	−	1280^b	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b
	FU	40		+	2560	160	20	Neg	113					2560	Neg	Neg	Neg	Neg	Neg	Neg
483	Adm	7	Comp	+	2560	Neg	Neg	Neg	Neg			Conf	−	2560 ^b	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b
	FU	21		+	2560	20	20	Neg	20	Neg	Neg			2560 ^b	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b
884	Adm	5	Comp	+	2560	40	Neg	Neg	40	Neg	40	Conf	−	1280^b	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b
	FU	19		+	2560	Neg	Neg	Neg	20				−	2560 ^b	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b	Neg^b
1074	Adm	6	Comp	Eq	452		Neg^b	Neg	Neg			Conf
	FU	84		+	1810	40	40	Neg	80				−	1280^b	Neg^b	Neg^b	Neg^b	Neg^b		Neg^b
1180	Adm	7	Comp	+	1280	452	640	452	160	Neg		Conf	−	1280^b	Neg^b	Neg^b	Neg^b	Neg^b		Neg^b
	FU	13		+	2560	226	226	160	160	20	80
2053	Adm	5	Comp	+	2560	20	Neg	Neg	Neg			Conf	−	2560	Neg	Neg	Neg	Neg
	FU	18		+	1280	80	Neg	40	Neg				−
775	Adm	3	Comp	−	320	Neg	Neg		Neg			Comp	−^a	113	Neg	Neg	Neg
	FU	12		+	640	Neg	Neg		40					640	Neg	Neg	Neg

5149	Adm	1	Unkn	+	2560	2560	2560	2560	2560			Conf		1280^b	20^b	20^b	20^b	Neg^b
	FU	28		+	2560	2560	2560	2560	2560				−	2560 ^b	40^b	20^b	40^b	20^b		Neg^b
1056	Adm	3	Unkn	+	320	1810	320	320	320	28	40	Conf	−	640^b	20^b	Neg^b	Neg^b	Neg^b		Neg^b
	FU	28		+	2560
1917	Adm	7	Unkn	+	2560	2560	2560	Neg	453			Conf	−	2560	Neg	Neg	Neg	Neg
	FU	12		+	1280	2560	2560	Neg	320				−	1280	Neg	Neg	Neg	Neg
1036	Adm	4	Unkn	+	80	2560	226	320	226	Neg	20	Neg	−	Neg^b	80^b	Neg^b	20^b	Neg^b		Neg^b
	FU	16		+	640	2560 ^b	1280	2560

Adm: serum on admission; FU: serum at follow-up; NAb: NAb assessed by VNT, geometric mean calculated from duplicate results, = indeterminate, NAb titre underlined to indicate the maximum dilution tested, neg: no NAb detected in duplicate samples (observation of cytopathic effect) for all serum dilutions tested (lowest = 20); NAb titre ≥40 considered as positive; D1–4: dengue virus 1–4; ZIK: Zika virus; WN: West Nile virus; class: classification for JE status according to criteria in Table 2; Conf: confirmed; Comp: compatible; Unkn: unknown; JEV IgG: anti-JEG IgG detection by ELISA (Euroimmun); +: positive; Eq: equivocal; −: negative.

^aJEV IgG negative before depletion.

^bOnly one replicate tested or interpretable, the other samples were tested in duplicate.